B2B SaaS Provider · vs · B2B SaaS Provider · B2C Consumer App / Platform
CGI vs Edenred
Structured technology and market comparison · 2026
Direct Feature Comparison
CGI · vs · EdenredEnterprise consulting and vertical software provider for regulated industries.
Specialised payment platforms for employee benefits, mobility and B2B finance.
Analyze all overlapping signals and tech stacks for CGI and Edenred
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between CGI and Edenred?
When comparing CGI and Edenred, both platforms operate within the Conversational AI & Chatbots, B2B SaaS Provider, and Measurement & Analytics Platform ecosystem. CGI is positioned as Enterprise consulting and vertical software provider for regulated industries, whereas Edenred focuses on Specialised payment platforms for employee benefits, mobility and B2B finance. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to CGI and Edenred?
When evaluating CGI and Edenred, enterprise buyers also consider other platforms in Conversational AI & Chatbots, B2B SaaS Provider, and Measurement & Analytics Platform. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of CGI and Edenred compare?
CGI is headquartered in Canada (founded in 1976) with >5,000 employees. Edenred is based in France (founded in 2010) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: CGI vs Edenred
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
CGI
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for CGI (2026-11-03)
On November 3, 2026, Corcept Therapeutics Incorporated furnished a Form 8-K under Items 2.02 and 7.01 announcing the release of its financial results for the third quarter ended September 30, 2026, along with a corporate update. The detailed financial statements and operational metrics were provided via an accompanying press release attached as Exhibit 99.1. The filing fulfills regulatory disclosure requirements under Regulation FD without formal incorporation into Securities Act registration statements.
- Corcept Therapeutics furnished its Q3 2026 financial results for the period ended September 30, 2026, via an 8-K press release notice on November 3, 2026.
- The disclosure was furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), with Exhibit 99.1 containing the full press release.
- The filing was formally signed and authorized by Chief Financial Officer Atabak Mokari on November 3, 2026.
- ·SEC APIfinancials
10-Q Financial Filing Analysis for CGI (2026-11-03)
Corcept Therapeutics reported significant financial growth for Q3 2026, driven by expanding commercial execution across its endocrinology franchise and the initial launch ramp of Lifyorli (relacorilant). Net product revenue rose 64.0% year-over-year to $340.5M, supported by $249.1M in hypercortisolism product sales and a $91.4M contribution from Lifyorli following its April 2026 U.S. launch. Operating income surged tenfold to $114.7M from $10.2M in Q3 2025, benefiting from gross margin expansion (cost of sales at just 1.4% of revenue) and disciplined operating expenditure leverage. Net income reached $126.8M, bolstered by a $6.5M net income tax benefit. Corcept maintains a robust balance sheet with $662.3M in cash and marketable securities and no long-term debt, positioning the company securely as it awaits the PDUFA target review date of December 17, 2026, for relacorilant in hypercortisolism.
- Q3 2026 net product revenue grew 64.0% year-over-year to $340.47M, with newly approved oncology drug Lifyorli contributing $91.41M and hypercortisolism products generating $249.07M.
- Operating income for the quarter reached $114.72M compared to $10.22M in Q3 2025, while diluted earnings per common share expanded to $1.01 compared to $0.16.
- The resubmitted New Drug Application (NDA) for relacorilant in endogenous hypercortisolism has an assigned PDUFA target action date of December 17, 2026.
- ·CGI
CGI named a Leader in the 2026 IDC MarketScape vendor assessment of worldwide trade finance systems
CGI has been named a Leader in the 2026 IDC MarketScape Worldwide Trade Finance Systems Vendor Assessment. The report highlights CGI Trade360, which supports operations in 98 countries and 348 bank locations with more than 247,000 corporate portal users. CGI Trade360 recently celebrated its 25th anniversary and processes over 15.5 million transactions annually. The recognition reflects CGI's investment in trade finance technology, AI integration, and client collaboration.
- On September 30, 2026, CGI announced it was named a Leader in the 2026 IDC MarketScape Worldwide Trade Finance Systems Vendor Assessment.
- CGI Trade360 supports operations in 98 countries and 348 bank locations, serving more than 247,000 corporate portal users.
- CGI Trade360 recently celebrated its 25th anniversary and processes more than 15.5 million transactions annually.
Edenred
Recent Signals
- ·Edenred
Basile Bourgnon remporte les 24h Ultim en Ocean Fifty et signe le doublé avec Edenred 5
Edenred announced that skipper Basile Bourgnon won the 24h Ultim race in the Ocean Fifty class aboard Edenred 5, covering the 354.80-nautical-mile course in 19 hours, 43 minutes and 13 seconds. He finished ahead of Matthieu Perraut (2nd) and Léonard Legrand (3rd), retaining his 2025 title and adding this win to his Drheam Cup victory earlier in summer 2026. The victory concludes Bourgnon's preparation for the Route du Rhum, where he aims to win.
- Edenred announced on September 28, 2026 that Basile Bourgnon won the 24h Ultim race in the Ocean Fifty class aboard Edenred 5.
- Bourgnon completed the 354.80-nautical-mile course in 19 hours, 43 minutes and 13 seconds, finishing at 08:43:13; Matthieu Perraut placed 2nd and Léonard Legrand 3rd.
- The victory was Bourgnon's second solo win of 2026 after the Drheam Cup in summer 2026 and he retained his 24h Ultim title from 2025.
- ·AdExchangerAI
Actionable Raises $10M to Build Causal AI for Customer Service
Actionable, a Paris-based AI-driven customer intelligence startup, has raised €8.5 million (approximately $10 million) in a funding round led by Hi inov, with participation from existing investor Axeleo Capital. Founded in 2024 by co-CEOs Nans Thomas and Nicolas Rieul, Actionable integrates data from CRMs, CDPs, transaction systems, and web analytics into a unified customer data model. The platform automatically reconstructs customer journeys to score entire customer bases daily on churn, satisfaction, complaint risk, and repeat purchase likelihood, providing causal insights for sectors like retail, financial services, insurance, transport, energy, telecoms, and automotive. Notable clients include Carrefour, SNCF, Engie, and Edenred. The funding will support US market entry via reseller partners, scaling the platform, hiring in product, engineering, and sales, and R&D in causal AI and deterministic modeling.
- Actionable raised €8.5 million ($10 million) in a funding round led by Hi inov, with participation from Axeleo Capital.
- Founded in 2024 by Nicolas Rieul and Nans Thomas, the platform predicts churn, satisfaction, complaint risk, and repeat purchases.
- The funding will support US expansion via reseller partners, sales hiring, and development of causal AI features.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners CGI and Edenred share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks